Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...

Adds ~24,000 net acres in Weld County and ~26 mboepd of oil-weighted (69% liquids) net productionAdds 77.9 MMboe and ~$1.1 Billion in Proved ...

The Shiloh Museum of Ozark History is kicking off 2025 with an exciting lineup of events and activities, offering something for everyone both at the museum and throughout the Ozarks. From programs on ...

Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer ... and does not constitute, represent or form part of any offer, ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ...

Faculty, staff and students will be required to sign in with their university credentials to access the recordings and feedback forms, which will be available through Monday, Feb. 10.